
    
      The study is a randomized, open-label crossover comparison study: This will be a 10-week
      open-label randomized study to evaluate the effect of inhaled PPP001 as compared to morphine
      sulfate to improve for the treatment of BTcP. After proper screening and verified
      inclusion/exclusion criteria, 20 consecutive subjects will be recruited.
    
  